Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biomarker identification of triple negative breast cancer subtypes using machine learning.

NPJ systems biology and applications·2026

Same author

Exploring the Landscape of Operating Room Scheduling: A Bibliometric Analysis of Recent Advancements and Future Prospects.

Biomedical engineering and computational biology·2025

Same author

Advancements and challenges in robotic surgery: A holistic examination of operational dynamics and future directions.

Surgery in practice and science·2025

Same author

Surgical Strategies in Renal Cancer: A Meta-analysis of Partial vs. Radical Nephrectomy Outcomes Across Tumor Stages.

Qatar medical journal·2025

Same author

Perception and Knowledge of Hospital Workers Toward Using Artificial Intelligence: A Descriptive Study.

Health science reports·2025

Same author

Author's Reply to Letter About: How to Write a Systematic Review and Meta-Analysis.

Diseases of the colon and rectum·2025

Search research articles

Related Experiment Video

Updated: May 19, 2026

Acupoint Catgut Embedding for Treatment of Chronic Pelvic Pain Due to the Sequelae of Pelvic Inflammatory Disease

Acupoint Catgut Embedding for Treatment of Chronic Pelvic Pain Due to the Sequelae of Pelvic Inflammatory Disease

Published on: May 3, 2024

Pregabalin for chronic prostatitis.

Omar M Aboumarzouk¹, Richard L Nelson

¹Deptartment of Urology, Wales Deanery, Cardiff, UK. aboumarzouk@gmail.com

The Cochrane Database of Systematic Reviews

|August 17, 2012

Summary

This summary is machine-generated.

Pregabalin did not significantly improve chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) symptoms in men, despite causing more neurological side effects. Further research is needed to determine its role in CP/CPPS symptom management.

More Related Videos

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis

Published on: January 16, 2013

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

Related Experiment Videos

Last Updated: May 19, 2026

Acupoint Catgut Embedding for Treatment of Chronic Pelvic Pain Due to the Sequelae of Pelvic Inflammatory Disease

Acupoint Catgut Embedding for Treatment of Chronic Pelvic Pain Due to the Sequelae of Pelvic Inflammatory Disease

Published on: May 3, 2024

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis

Published on: January 16, 2013

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

Area of Science:

Urology
Neurology
Pharmacology

Background:

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) significantly impacts men's quality of life.
Neuropathic origins are suspected for CP/CPPS, suggesting potential benefits from medications like pregabalin.

Purpose of the Study:

To compare pregabalin with other pain relief methods for CP/CPPS symptoms.
To evaluate the safety and effectiveness of pregabalin in improving specific CP/CPPS symptoms.

Main Methods:

A systematic search of multiple databases (CENTRAL, MEDLINE, EMBASE, CINAHL, clinicaltrials.gov, Google Scholar) was conducted for relevant studies.
Included were randomized controlled trials (RCTs) comparing pregabalin to placebo or other analgesics in CP/CPPS patients, excluding those with known pain causes.
Data was collected and analyzed from a single RCT that compared pregabalin to placebo for CP/CPPS management.

Main Results:

No significant difference in clinical response (≥6-point improvement) was observed between pregabalin and placebo groups (47.2% vs. 35.8%).
Pregabalin showed a greater reduction in pain scores compared to placebo (MD -2.3 points).
While 59% experienced side effects, no serious events occurred; however, neurological side effects were significantly higher with pregabalin (38.5% vs. 22.6%).

Conclusions:

One RCT suggests pregabalin does not improve CP/CPPS symptoms and is associated with a high percentage of adverse effects.
Further research is necessary to definitively establish pregabalin's role in managing CP/CPPS symptoms.